This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Jul;9(7):610-2.

doi: 10.1016/S1470-2045(08)70163-3.

Immunotherapeutic potential of oncolytic virotherapy

Robin J Prestwich, Kevin J Harrington, Richard G Vile, Alan A Melcher

PMID: 18598928
DOI: 10.1016/S1470-2045(08)70163-3

Comment

Immunotherapeutic potential of oncolytic virotherapy

Robin J Prestwich et al. Lancet Oncol. 2008 Jul.

. 2008 Jul;9(7):610-2.

doi: 10.1016/S1470-2045(08)70163-3.

Authors

Robin J Prestwich, Kevin J Harrington, Richard G Vile, Alan A Melcher

PMID: 18598928
DOI: 10.1016/S1470-2045(08)70163-3

No abstract available

PubMed Disclaimer

Comment on

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH. Park BH, et al. Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Lancet Oncol. 2008. PMID: 18495536 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information